ublituximab Report issue

Biologics mAb Approved FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

tg-1101 | ublitixiumab | ublituximab

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1/Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 3)

Lymphoma, Follicular (Phase 2/Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2/Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 2/Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Medial Collateral Ligament, Knee (Phase 1)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neuromyelitis Optica (Phase 1)

Squamous Intraepithelial Lesions (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 29
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue